Subscribe To
CRTX / Cortexyme: A Challenging Path Forward
CRTX News
By Benzinga
March 8, 2022
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related t more_horizontal
By Seeking Alpha
February 28, 2022
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases. more_horizontal
By Seeking Alpha
February 28, 2022
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases. more_horizontal
By Seeking Alpha
February 28, 2022
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases. more_horizontal
By Zacks Investment Research
February 18, 2022
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with more_horizontal
By Zacks Investment Research
February 18, 2022
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with more_horizontal
By Zacks Investment Research
February 18, 2022
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with more_horizontal
By Zacks Investment Research
February 2, 2022
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technic more_horizontal
